Skip to content

Author

L. Bastholt

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact.

BACKGROUND Immune checkpoint inhibitors (ICIs) have transformed outcomes in advanced melanoma, but optimal treatment duration remains unclear. Most patients are treated until two years, treatment limiting toxicity (TLT), or progression. This study evaluates real-world outcomes after elective discontinuation of ICIs fol...

R. Jurlander, T. H. Borch, S. Petersen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.